Please login to the form below

Not currently logged in
Email:
Password:

morphosys

This page shows the latest morphosys news and features for those working in and with pharma, biotech and healthcare.

Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys

Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys

Under the terms of the deal, Incyte is paying MorphoSys $750m upfront, as well as making an equity investment worth $150m in the company. ... MorphoSys is also eligible to receive milestone payments worth up to $1.1bn, in addition to any royalties from

Latest news

More from news
Approximately 5 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    Morphosys. One of Europe’s star performers over the last two to three years has been Germany’s Morphosys. ... Unlike many other European biotechs, Morphosys isn’t seeking a marketing partner for the launch of its lead product, and aims to go it

  • Deal Watch November 2016 Deal Watch November 2016

    acquisition - company. 125+. MorphoSys/ Leo Pharma. discovery and development of mAbs for skin diseases.

  • Pharma deals in March 2015 Pharma deals in March 2015

    In the same area is Morphosys which has been less fortunate this month because of the termination of its $818m agreement with Celgene to develop a Mab for treatment of multiple ... myeloma. Morphosys' share price fell by over 20%. This is an

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).

  • Pharma deals during August 2014 Pharma deals during August 2014

    These include the usual sprinkling of small molecule (Millennium/ Infinity, Hanmi/ Luye, Ziopharm/ Solasia) and antibody (Emergent/ Morphosys) approaches but also more alternative approaches as exemplified by the Gamida/ Novartis agreement.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...

Latest intelligence

Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...
InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....

Infographics